Needham raises Shattuck Labs stock price target on HS trial plans
Needham raised its price target for Shattuck Labs (STTK) to $19 from $17, citing plans for a Phase 2 trial of SL-325 in hidradenitis suppurativa. The stock has surged 87% year-to-date, with analysts maintaining a strong buy consensus. The company expects trial data in 2028, and the hidradenitis suppurativa market is projected to reach $5 billion by 2030. Multiple analysts have recently evaluated STTK, with varying price targets and ratings.
How this was made
The 30-second read
Why it matters
The upgrade may attract short‑term buying and lift the stock toward the new $19 target.
Market read
Analyst price target raise provides fresh catalyst for STTK, a micro‑cap biotech.
What to watch
Potential competition from Merck's TL1A program and the need for later‑stage data.
Background
Needham's upgrade follows Shattuck Labs' announcement of a Phase 2 trial start for its anti‑DR3 antibody SL‑325 in hidradenitis suppurativa, with topline data expected in 2028.
Ticker impact
Needham raised its price target on Shattuck Labs (STTK) to $19 and highlighted the upcoming Phase 2 hidradenitis suppurativa trial for SL-325.
likely upward pressure as investors price in the trial start and higher target.
The price target increase and buy rating reflect fresh, material information about a new trial that could drive revenue growth.
Market effects
Strengthens the biotech sector's focus on inflammatory disease pipelines.
U.S. biotech investors may increase exposure to early‑stage immunology assets.
Limited to investors tracking US‑listed biotech companies.
Counterpoint
The trial is still early; execution risk could delay or diminish revenue impact.
Key entities
- companyShattuck Labs
Biotech firm developing SL‑325 for inflammatory diseases.
- analystNeedham
Equity research firm raising price target on STTK.
